IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0618534
(2009-11-13)
|
등록번호 |
US-8450357
(2013-05-28)
|
발명자
/ 주소 |
- Soll, Mark David
- Cramer, Luiz Gustavo
- Pate, James
- Shub, Natalya
- Le Hir de Fallois, Loic Patrick
- Timmons, Philip Reid
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 |
피인용 횟수 :
2 인용 특허 :
67 |
초록
▼
This invention relates to compositions for combating parasites in animals, comprising 1-arylpyrazole compounds alone or in combination with formamidine compounds. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infestation in an animal compr
This invention relates to compositions for combating parasites in animals, comprising 1-arylpyrazole compounds alone or in combination with formamidine compounds. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infestation in an animal comprising administering the compositions of the invention to the animal in need thereof.
대표청구항
▼
1. A composition for the treatment of a parasitic infestation in an animal comprising at least one 1-arylpyrazole compound of formula (IB): wherein:R1b is alkyl, CN or halogen;R2b is S(O)nR14b or 4,5-dicyanoimidazol-2-yl or haloalkyl;R14b is alkyl or haloalkyl;R3b is a hydrogen, halogen, —NR7b R8b,
1. A composition for the treatment of a parasitic infestation in an animal comprising at least one 1-arylpyrazole compound of formula (IB): wherein:R1b is alkyl, CN or halogen;R2b is S(O)nR14b or 4,5-dicyanoimidazol-2-yl or haloalkyl;R14b is alkyl or haloalkyl;R3b is a hydrogen, halogen, —NR7b R8b, —S(O)m R9b, —C(O)R9b, —C(O)OR9b, alkyl, haloalkyl, —OR10b or an —N═C(R11b)(R12b);R6b is a halogen, haloalkyl, haloalkoxy, S(O)q CF3 or SF5 group;R7B and R8B independently represent a hydrogen, alkyl, haloalkyl, —C(O)alkyl, —S(O)rCF3, acyl or alkoxycarbonyl; orR7b and R8b can together form a divalent alkylene radical which is optionally interrupted by one or two divalent heteroatoms;R9b is an alkyl or haloalkyl;R10b is hydrogen, alkyl or haloalkyl;R11b is hydrogen or alkyl radical;R12b is an optionally substituted aryl or an optionally substituted heteroaryl group;R4b and R13b represent, independently of one another, hydrogen, halogen CN or NO2;m, n, q and r represent, independently of one another, an integer equal to 0, 1 or 2; andZ represents a trivalent nitrogen atom or a C-R13b radical, the three other valencies of the carbon atom forming part of the aromatic ring,in a first veterinarily acceptable carrier;at least one formamidine compound of formula (II): wherein:x is an integer from 0-5;R14 is alkyl, halogen or —OC(═O)NRaRb, wherein Ra and Rb are independently hydrogen or alkyl;R15 is hydrogen or alkyl;R16 is hydrogen or alkyl; andR17 is hydrogen, alkyl or in a second veterinarily acceptable carrier; and optionally at least one crystallization inhibitor, wherein the 1-arylpyrazole compound(s) and first veterinarily acceptable carrier are compartmentalized together, and not in fluid communication with, the formamidine compound(s) and the second veterinarily acceptable carrier. 2. The composition of claim 1, wherein the 1-arylpyrazole compound(s) of Formula (IB) and the first veterinarily acceptable carrier are in one cavity of a dual-cavity container and the formamidine compound(s) of Formula (II) and the second veterinarily acceptable carrier are in a second cavity of a dual-cavity container, wherein the first cavity is defined by a front wall and a divider wall; and the second cavity is defined by a rear wall and the divider wall. 3. The composition of claim 1, wherein in the 1-arylpyrazole of Formula (IB): R1b is methyl, CN or halogen;R2b is S(O)nR14b;R14b is C1-C6-alkyl or C1-C6-haloalkyl;R3b is —NR7bR8b,R7b and R8b independently represent a hydrogen, C1-C6-alkyl, C1-C6-haloalkyl, —C(O)C1-C6-alkyl, —S(O)rCF3, C1-C6-acyl or C1-C6-alkoxycarbonyl radical;R6b is a halogen, C1-C6-haloalkyl, or C1-C6-haloalkoxy;m, n, q and r represent, independently of one another, an integer equal to 0 or 1; andZ is a C-R13b radical. 4. The composition of claim 1, wherein in the 1-arylpyrazole of Formula (IB): R1b is methyl, CN or halogen;R2b is S(O)nR14b;R14b is C1-C6-alkyl or C1-C6-haloalkyl;R3b is alkyl or haloalkyl;R6b is a halogen, C1-C6-haloalkyl, or C1-C6-haloalkoxy;m, n, q and r represent, independently of one another, an integer equal to 0 or 1; andZ is a C—R13b radical. 5. The composition of claim 1, wherein the first veterinarily acceptable carrier comprises acetone, acetonitrile, benzyl alcohol, ethanol, isopropanol, diisobutyl adipate, diisopropyl adipate, butyl diglycol, dipropylene glycol n-butyl ether, ethylene glycol monoethyl ether, ethylene glycol monomethyl ether, dipropylene glycol monomethyl ether, liquid polyoxyethylene glycols, propylene glycol monomethyl ether, propylene glycol monoethyl ether, 2-pyrrolidone, N-methylpyrrolidone, diethylene glycol monoethyl ether, triacetin, butyl acetate, octyl acetate, propylene carbonate, butylene carbonate, dimethyl sulfoxide, an amide, dimethylformamide, dimethylacetamide, or any combination thereof. 6. The composition of claim 1, wherein the second veterinarily acceptable carrier comprises aryl ethers, alkoxybenzene compounds, aliphatic carboxylic acid esters, aromatic carboxylic acid esters, aliphatic ketones, cyclic ketones, or mixtures thereof. 7. The composition of claim 1, wherein the second veterinarily acceptable carrier comprises methoxybenzene, butyl acetate, benzyl acetate, methyl isobutyl ketone, ethyl benzoate, benzyl benzoate, octyl acetate, or mixtures thereof. 8. The composition of claim 1, wherein the second veterinarily acceptable carrier comprises an aprotic solvent with a dielectric constant of about 2 to about 30. 9. The composition of claim 1, wherein at least one formamidine compound is amitraz, formetanate, chloromebuform, formparanate or chlodimeform. 10. A method for the treatment of a parasitic infestation in an animal comprising administering an effective amount of the composition of claim 1 to the animal. 11. The method of claim 10, wherein at least one 1-arylpyrazole compound is fipronil. 12. The method of claim 10, wherein at least one formamidine compound is amitraz. 13. The method of claim 10, wherein the composition is administered using a dual-cavity container, wherein the 1-arylpyrazole compound(s) and the first veterinarily acceptable carrier are administered from a first cavity of the dual-cavity container and the formamidine compound(s) and the second veterinarily acceptable carrier are administered from a second cavity of the dual-cavity container. 14. The method of claim 12, wherein the 1-arylpyrazole compound(s) and the formamidine compound(s) are administered simultaneously. 15. The composition of claim 1, wherein the first veterinarily acceptable carrier comprises an organic solvent with a dielectric constant of about 10 to about 35. 16. The composition of claim 15, wherein the first veterinarily acceptable carrier comprises C1-C10 alcohols or esters thereof, C10-C18 saturated fatty acids or esters thereof, C10-C18 monounsaturated fatty acids or esters thereof, monoesters or diesters of aliphatic diacids, glycerol monoesters, glycerol diesters, glycerol triesters, glycols, glycol ethers, glycol esters, glycol carbonates, polyethylene glycols or monoethers, diethers, monoesters or diesters thereof. 17. The composition of claim 16, wherein the first veterinarily acceptable carrier comprises a C1-C10 alcohol, a glycol ether, a polyethylene glycol monoether or a polyethylene glycol diether, or a mixture thereof. 18. The composition of claim 1, wherein the 1-arylpyrazole of Formula (IB) is fipronil. 19. The composition of claim 1, wherein the 1-arylpyrazole of Formula (IB) is amitraz. 20. The composition of claim 18, wherein fipronil is present at a concentration of about 5% (w/v) to about 15% (w/v). 21. The composition of claim 19, wherein amitraz is present at a concentration of about 1% (w/v) to about 30% (w/v). 22. The composition of claim 1, wherein the composition comprises fipronil at a concentration of about 5% (w/v) to about 15% (w/v) and amitraz at a concentration of about 5% (w/v) to about 20% (w/v). 23. The composition of claim 1, wherein the composition further comprises an additional parasiticidal active agent. 24. The composition of claim 23, wherein the additional parasiticidal active agent is an avermectin or milbemycin compound, an insect growth regulator, a pyrethroid, a benzimidazole, an imidazothiazole, praziquantel, an isoxazoline compound, an amino acetonitrile compound or an aryloazol-2-yl cyanoethylamino compound. 25. The composition of claim 24, wherein the insect growth regulator is methoprene or pyriproxyfen. 26. The composition of claim 24, wherein the avermectin or milbemycin compound is abamectin, dimadectin, doramectin, emamectin, eprinomectin, ivermectin, latidectin, lepimectin, selamectin, milbemectin, milbemycin D, moxidectin, nemadectin or milbemycin oxime. 27. The composition of claim 1, wherein the composition comprises fipronil at a concentration of about 5% (w/v) to about 15% (w/v) and amitraz at a concentration of about 5% to about 20% (w/v); wherein the first veterinarily acceptable carrier comprises ethanol, isopropanol, diethyleneglycol monoethyl ether, N-methylpyrrolidone, or a mixture thereof; and wherein the second veterinarily acceptable carrier comprises methoxybenzene, butyl acetate, benzyl acetate, ethyl benzoate, benzyl benzoate or octyl acetate, or a mixture thereof.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.